Genscript Biotech Corporation (HKG:1548)
Hong Kong · Delayed Price · Currency is HKD 18.06
+0.86 (5.00%)
Jul 31, 2026, 4:08 PM HKT
Genscript Biotech Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, Genscript Biotech stock has a consensus rating of "Strong Buy" and an average price target of $17.76. The average 1-year stock price forecast is 1.66% lower than the current stock price, while the lowest is $15.51 (-14.12%) and the highest is $21.04 (+16.50%).
Price Target: $17.76 (-1.66%)
Analyst Consensus: Strong Buy
Price Target
Chart* Price targets were last updated on May 14, 2026.
Analyst Ratings
The average analyst rating for Genscript Biotech stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 6 | 6 | 6 | 6 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst Guotai Haitong No rating | Guotai Haitong | Buy Maintains $25.57 | Buy | Maintains | $25.57 | +41.58% | May 14, 2026 |
| Jefferies | Jefferies | Buy Maintains $15.50 | Buy | Maintains | $15.50 | -14.17% | Apr 3, 2026 |
Unknown Analyst J.P. Morgan No rating | J.P. Morgan | Buy Maintains $24.00 → $20.00 | Buy | Maintains | $24.00 → $20.00 | +10.74% | Mar 19, 2026 |
Unknown Analyst CICC No rating | CICC | Buy Maintains $17.90 | Buy | Maintains | $17.90 | -0.89% | Mar 19, 2026 |
Unknown Analyst Huatai Securities No rating | Huatai Securities | Buy Maintains $16.26 | Buy | Maintains | $16.26 | -9.97% | Mar 18, 2026 |
Financial Forecast
Revenue This Year
819.08M
from 959.53M
Decreased by -14.64%
Revenue Next Year
938.47M
from 819.08M
Increased by 14.58%
EPS This Year
0.03
from 0.11
Decreased by -67.17%
EPS Next Year
0.06
from 0.03
Increased by 79.71%
EPS and Forward PE are based on non-GAAP adjusted numbers.